BRISTOL-MYERS SQUIBB COMPANY Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $252.00 million for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-18.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2011-02-18
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2010-12-31 was $41.00M, a 2.38% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2010-09-30 was $89.00M, a 2866.67% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2010-06-30 was $40.00M.
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2010-03-31 was $82.00M.
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2010 was $252.00M, a 460.00% increase from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2009 was $45.00M, a 800.00% increase from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2008 was $5.00M, a 98.50% decline from fiscal 2007.
- BRISTOL-MYERS SQUIBB COMPANY proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2007 was $333.00M.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2010-12-31 | $41.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $130.00M derived: sum of 2 quarters · filed 2011-02-18 | $170.00M derived: sum of 3 quarters · filed 2011-02-18 | $252.00M 10-K · filed 2011-02-18 |
| 2010-09-30 | $89.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $129.00M derived: sum of 2 quarters · filed 2010-10-26 | $211.00M 10-Q · filed 2010-10-26 | $253.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2010-06-30 | $40.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-22 | $122.00M 10-Q · filed 2010-07-22 | $164.00M derived: sum of 3 quarters · filed 2011-02-18 | $167.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2010-03-31 | $82.00M 10-Q · filed 2010-04-29 | $124.00M derived: sum of 2 quarters · filed 2011-02-18 | $127.00M derived: sum of 3 quarters · filed 2011-02-18 | |
| 2009-12-31 | $42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $45.00M derived: sum of 2 quarters · filed 2011-02-18 | $45.00M 10-K · filed 2011-02-18 | |
| 2009-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $3.00M 10-Q · filed 2010-10-26 | ||
| 2009-06-30 | $0.00 10-Q · filed 2009-07-23 | |||
| 2008-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $1.00M derived: sum of 2 quarters · filed 2011-02-18 | $5.00M 10-K · filed 2011-02-18 | |
| 2008-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-22 | $4.00M 10-Q · filed 2009-10-22 | ||
| 2008-06-30 | $4.00M 10-Q · filed 2009-07-23 | |||
| 2007-12-31 | $333.00M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |